Navigation Links
Physicians Group Calls on the FDA to Repurpose Enbrel for the Treatment of TBI, Stroke and Alzheimer’s Disease
Date:2/6/2013

(PRWEB) February 06, 2013

The growing body of published observational data showing significant and rapid improvement in physical motor impairments, spasticity, memory and cognitive function following perispinal Enbrel treatment warrants the commencement of rigorous clinical trials leading to the repurposing of Enbrel for the treatment of traumatic brain injury (TBI), stroke and Alzheimer’s disease. Physicians Augusto Ramirez, M.D.CEO of Neurological Wellness Center: http://www.neurological-recovery-guide.com/, Eugenia Siezar, M.D. and Meylin Acuna, M.D. petition the FDA to take immediate steps leading to the repurposing of Enbrel for the treatment of TBI, stroke and Alzheimer’s disease.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua, Nicaragua authorized this press release.

Today Neurological Wellness Center remains the only institution in the world providing individualized instructional courses teaching this perispinal Enbrel injection procedure. For more information about Neurological Wellness Center’s perispinal Enbrel injection courses, visit: http://reversealzheimersnow.com/

In 2012 Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and e-book are now available online for $49. Visit: http://www.neurological-recovery-guide.com/

Perispinal Enbrel injections effectively treat conditions for which no other treatment is currently available. An observational study was published in December 2012 in the journal CNS Drugs and is available online, http://www.ncbi.nlm.nih.gov/pubmed/23100196

Systematically examined the clinical responses of 629 patients afflicted by stroke or traumatic brain injury following the perispinal administration of Enbrel (etanercept), the mean interval between stroke and perispinal Enbrel (PSE) treatment was 42 months. The mean interval between TBI and PSE treatment was 115 months. The fact that there is presently no FDA-approved treatment that can effectively ameliorate the impairments of stroke or TBI, 42 to 115 months after the event, makes it clear that PSE treatment satisfies the criteria qualifying for the FDA’s fast track drug development program by “demonstrating the potential to address unmet medical needs” under section 506(a) of the Fast Track Drug Development Act. 4. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf. This is the only treatment of TBI that has the capacity to meaningfully restore function one year or longer after the brain injury.

The case for FDA fast tracking PSE for the treatment of Alzheimer’s disease is just as compelling. There have been more than a dozen published studies showing a significant and rapid cognitive improvement following PSE since Dr. Tobinick’s ground-treaking pilot study published in the journal Medscape in 2006 and available online. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785182/. This is the only Alzheimer's disease treatment that enables the recovery of memory and cognitive function. Frequently this treatment of Alzheimer's disease results in noticeable improvements within minutes. One need only to engage in conversation or look into their eyes to notice a striking change.

Every day countless thousands of people in the U.S. and around the world must move to assisted living facilities because the drugs currently available are failing to halt the progression of this disease. We at Neurological Wellness Center lament that physicians from around the world must travel to Managua Nicaragua to receive this instruction. FDA approval of PSE as a treatment for TBI, stroke and Alzheimer’s disease would result in medical schools around the world incorporating perispinal Enbrel injection technique into the standard curriculum.

Enbrel has been approved for the treatment of rheumatoid arthritis and psoriasis since 1998. It is being aggressively marketed by Amgen/Pfizer earning them over $5 Billion annually. Over 400,000 Americans are currently taking Enbrel. A box of 25 mg vials typically retails for $1000. To purchase boxes of Enbrel for as low as $765/ box visit: http://www.genuine-enbrel-cheaper.com/. The safety parameters of Enbrel are well established. To access the 173 references in support of the assertions in this press release, click the file attachment at the right side of this page.

Neurological Wellness Center invites physicians and concerned lay persons to contact Amgen requesting the repurposing of Enbrel for the treatment of TBI, stroke and Alzheimer's disease, attention Huong Nguyen; medinfo(at)amgen(dot)com Tel: 805-447-1000 Fax: 805-447-1010.

Food and Drug Administration
Center for Drug Evaluation and Research
5600 Fishers Lane, Rockville, MD 20857
(Tel) 301-827-4573

Read the full story at http://www.prweb.com/releases/2013/2/prweb10319406.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Are deaf and hard-of-hearing physicians getting the support they need?
2. Majority of primary care physicians prefer delivering radiology test results to patients themselves
3. Physicians brain scans indicate doctors can feel their patients pain -- and their relief
4. Subodh Verma wins Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery
5. Corporate Whistle Blower Center Urges ER Physicians Or Hospital Staff To Turn In Hospitals Admitting Patients For Medicare Fraud For Huge Whistleblower Rewards
6. Complex spinal surgeries with 2 attending physicians, instead of 1, benefit patients
7. American College of Physicians calls for immunizations for all health care providers
8. COLA to offer lab quality program to American College of Physicians
9. Corporate Whistle Blower Center Now Urges Physicians Medical Device and Drug Industry Insiders To Step Up-If They Have Proof Of Serious Wrongdoing or Overbilling
10. Most physicians do not meet Medicare quality reporting requirements
11. Corporate Whistle Blower Center Now Urges Physicians to Become a Whistleblower if They Have Proof a Medical Device or a Drug Product was Defective-and it was Sold Anyway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... Grocery Company to the list of fine retailers selling biodegradable, hanging flushable wipes ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more than ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for Health Care ... of America (HCAOA). This agreement allows HCAOA members to receive special pricing on ... on Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back ... joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified ... The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike ...
(Date:4/28/2017)... MA (PRWEB) , ... April 28, 2017 , ... People ... for older people. “Wearing a hearing aid doesn’t have the stigma it had when ... & Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... 18, 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), ... Urology, Uro/Gyn and Gynecology markets with innovative and proprietary ... ended March 31, 2017 after the market close on ... will host a conference call and webcast to discuss ... 2, 2017 at 4:30 p.m. Eastern Time (3:30 p.m. ...
Breaking Medicine Technology: